data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
Watch
YouTube
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
CytomX Therapeutics
(NASDAQ:CTMX)
CytomX Therapeutics, Inc. - Common Stock is expected to split Monday, August 15, 2022 with a ratio of 1:5
CytomX Therapeutics, Inc. - Common Stock recently split on Friday, August 12, 2022 with a ratio of 1:3
$1.67
0.14[9.15%]
At close: Aug 12
$1.62
-0.0500[-2.99%]
After Hours: 4:24PM EDT
Day High/Low1.53 - 1.69
52 Week High/Low1.19 - 4.73
Open / Close1.55 / 1.67
Float / Outstanding65.2M / 66M
Vol / Avg.1.1M / 1.9M
Mkt Cap110.1M
P/E-
50d Avg. Price1.62
Div / Yield-
Payout Ratio-
EPS-0.37
Total Float65.2M

CytomX Therapeutics (NASDAQ:CTMX), Quotes and News Summary

CytomX Therapeutics (NASDAQ: CTMX)

Day High/Low1.53 - 1.69
52 Week High/Low1.19 - 4.73
Open / Close1.55 / 1.67
Float / Outstanding65.2M / 66M
Vol / Avg.1.1M / 1.9M
Mkt Cap110.1M
P/E-
50d Avg. Price1.62
Div / Yield-
Payout Ratio-
EPS-0.37
Total Float65.2M
Sector: Health Care.Industry: Biotechnology
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The company focuses on developing Probody therapeutics which addresses clinically-validated cancer targets in immuno-oncology that are difficult to drug and lead to concerns about damage to healthy tissues or toxicities.
Read More

Earnings

see more
FY 2023Est.ActualSurprise
EPS
(EXPECTED)2023-12-20
REV
FY 2023Est.ActualSurprise
EPS
(EXPECTED)2023-11-09
REV

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

CytomX Therapeutics Questions & Answers

Q
How do I buy CytomX Therapeutics (CTMX) stock?
A

You can purchase shares of CytomX Therapeutics (NASDAQ: CTMX) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are CytomX Therapeutics's (CTMX) competitors?
Q
What is the target price for CytomX Therapeutics (CTMX) stock?
A

The latest price target for CytomX Therapeutics (NASDAQ: CTMX) was reported by Cantor Fitzgerald on Friday, August 12, 2022. The analyst firm set a price target for 4.00 expecting CTMX to rise to within 12 months (a possible 139.52% upside). 50 analyst firms have reported ratings in the last year.

Q
Current Stock Price for CytomX Therapeutics (CTMX)?
A

The stock price for CytomX Therapeutics (NASDAQ: CTMX) is $1.67 last updated August 12, 2022, 8:00 PM UTC.

Q
Does CytomX Therapeutics (CTMX) pay a dividend?
A

The next CytomX Therapeutics (CTMX) dividend date is projected to be Thursday, September 1, 2022.

Q
When is CytomX Therapeutics (NASDAQ:CTMX) reporting earnings?
A

CytomX Therapeutics’s FY earnings are confirmed for Wednesday, December 20, 2023.

Q
Is CytomX Therapeutics (CTMX) going to split?
A

There is no upcoming split for CytomX Therapeutics.

Q
What sector and industry does CytomX Therapeutics (CTMX) operate in?
A

CytomX Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.